Diabetes Care - McMaster Experts

publication venue for

Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes 2019
A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity.. 47:2017-2023. 2024
Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk. 47:259-266. 2024
Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. 46:1524-1530. 2023
The Growing Role of Technology in the Care of Older Adults With Diabetes. 46:1455-1463. 2023
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis. 46:1046-1051. 2023
Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466–2475. 46:e112-e112. 2023
Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial. 45:2862-2870. 2022
Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis. 45:e146-e147. 2022
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. 45:2152-2155. 2022
Enrollment of Black, Indigenous, and Other People of Color in Multicountry Randomized Controlled Trials of Diabetes Conducted in North America and Europe. 45:e116-e117. 2022
Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691. 45:e111-e112. 2022
Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. 45:684-691. 2022
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. 45:547-554. 2022
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. 45:178-185. 2022
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. 44:2438-2444. 2021
Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters. 44:2212-2215. 2021
Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus. 44:1860-1867. 2021
Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. 44:1309-1316. 2021
Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. 44:e85-e86. 2021
Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. 44:e6-e8. 2021
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. 44:290-296. 2021
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. 44:164-173. 2021
Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. 43:3094-3101. 2020
White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries. 43:2643-2650. 2020
Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. 43:2242-2247. 2020
Adolescent Obesity and Early-Onset Type 2 Diabetes. 43:1487-1495. 2020
Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. 43:1553-1556. 2020
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. 43:835-842. 2020
Novel Biomarkers for Change in Renal Function in People With Dysglycemia. 43:433-439. 2020
Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. 43:145-151. 2020
Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. 42:1800-1808. 2019
The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. 42:1159-1161. 2019
Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. 42:1136-1146. 2019
Dysglycemia and the Density of the Coronary Vasa Vasorum. 42:980-982. 2019
Frailty and Risk of Fractures in Patients With Type 2 Diabetes. 42:507-513. 2019
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. 42:142-147. 2019
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. 41:2404-2413. 2018
A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. 41:1121-1124. 2018
Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. 41:348-355. 2018
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum. 41:14-31. 2018
Maturation of CGM and Glycemic Measurements Beyond HbA1c—A Turning Point in Research and Clinical Decisions. 40:1611-1613. 2017
Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications. 40:1500-1505. 2017
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. 40:280-283. 2017
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201. 40:e23-e24. 2017
BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents. 39:1996-2003. 2016
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. 39:1915-1924. 2016
Making a Difference With Diabetes Research and Care. 39:1309-1310. 2016
Response to Comments on Fedorko et al. Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care 2016;39:392–399. 39:e136-e137. 2016
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. 39:1089-1100. 2016
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. 39:1186-1201. 2016
Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). 39:709-716. 2016
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. 39:701-708. 2016
Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. 39:780-787. 2016
Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. 39:392-399. 2016
Statement of Retraction. Nuts as a Replacement for Carbohydrates in the Diabetic Diet. Diabetes Care 2011;34:1706–1711. DOI: 10.2337/dc11-0338. 39:319-319. 2016
Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074. 38:e170-e171. 2015
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. 38:1558-1566. 2015
Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. 38:793-800. 2015
Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial. 38:22-28. 2015
Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial. 37:3279-3285. 2014
The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. 37:3244-3252. 2014
Cognitive Function and the Risk for Diabetes Among Young Men. 37:2982-2988. 2014
Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults. 37:2989-2995. 2014
Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. 37:e217-e217. 2014
Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. 37:e223-e223. 2014
Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial. 37:1806-1814. 2014
Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. 37:1721-1728. 2014
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. 37:1360-1366. 2014
Response to Comment on Shah et al. Cardiovascular Complications and Mortality After Diabetes Diagnosis for South Asian and Chinese Patients: A Population-Based Cohort Study. Diabetes Care 2013;36:2670–2676. 37:e80-e80. 2014
Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study. 37:604-610. 2014
Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. 37:634-643. 2014
Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes. 36:3599-3606. 2013
Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. 36:2915-2922. 2013
Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922. 36:e181-e181. 2013
Cardiovascular Complications and Mortality After Diabetes Diagnosis for South Asian and Chinese Patients. 36:2670-2676. 2013
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. 36:2466-2474. 2013
Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. 36:2836-2842. 2013
Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. 36:2162-2168. 2013
Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. 36:1266-1271. 2013
Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function. 36:1172-1180. 2013
Effect of Fructose on Glycemic Control in Diabetes. 35:1611-1620. 2012
Absence of Disparities in the Quality of Primary Diabetes Care for South Asians and Chinese in an Urban Canadian Setting. 35:794-796. 2012
Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes. 35:787-793. 2012
Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes. 35:749-753. 2012
Screening for Dysglycemia in Overweight Youth Presenting for Weight Management. 35:711-716. 2012
Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit. 35:19-24. 2012
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes. 34:1902-1907. 2011
Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community. 34:1794-1798. 2011
Nuts as a Replacement for Carbohydrates in the Diabetic Diet. 34:1706-1711. 2011
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. 34:1265-1269. 2011
Lifestyle Interaction With Fat Mass and Obesity-Associated (FTO) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. 34:675-680. 2011
Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes (vol 33, pg 1379, 2010). 34:247-247. 2011
Errata. 34:247-247. 2011
Ethnicity and Sex Affect Diabetes Incidence and Outcomes. 34:96-101. 2011
Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. 33:2558-2560. 2010
Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). 33:2558-2560. 2010
Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. 33:2250-2253. 2010
The Effect of Oral Antidiabetic Agents on A1C Levels. 33:1859-1864. 2010
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. 33:1578-1584. 2010
Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. 33:1629-1634. 2010
Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. 33:1629-1634. 2010
A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. 33:1176-1178. 2010
Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. 33:1379-1381. 2010
Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. 33:608-613. 2010
Heterogeneous Effects of Fructose on Blood Lipids in Individuals With Type 2 Diabetes. 32:1930-1937. 2009
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. 32:e58-e58. 2009
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. 32:915-920. 2009
Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. 32:221-226. 2009
Dysglycemia and a History of Reproductive Risk Factors. 31:1635-1638. 2008
Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. 31:1007-1014. 2008
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events. 30:389-394. 2007
Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. 30:432-434. 2007
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. 30:162-172. 2007
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. 30:188-189. 2007
Metabolic Syndrome. 29:2471-2476. 2006
Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome. 28:2556-2562. 2005
Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects. 28:1630-1635. 2005
The Burden of Treatment Failure in Type 2 Diabetes. 28:761-762. 2005
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control. 28:229-230. 2005
Telecare for Patients with Type 1 Diabetes and Inadequate Glycemic Control. 28:228-229. 2005
Comparative Roles of Microvascular and Nerve Function in Foot Ulceration In Type 2 Diabetes. 27:3026-3026. 2004
The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes. 27:2767-2767. 2004
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control. 27:1088-1094. 2004
Utility of B-Type Natriuretic Peptide (BNP) as a Screen for Left Ventricular Dysfunction in Patients With Diabetes. 26:2081-2087. 2003
Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population. 26:290-296. 2003
The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada. 26:144-149. 2003
Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes. 25:1919-1927. 2002
A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes. 25:1576-1583. 2002
The Economic Cost of Diabetes in Canada, 1998. 25:1303-1307. 2002
Fasting Versus Postload Glucose Levels. 24:1855-1857. 2001
Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction.. 23:882-883. 2000
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.. 23 Suppl 2:B35-B39. 2000
Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction.. 23:377-380. 2000
Is glucose a continuous risk factor for cardiovascular mortality?. 22:659-660. 1999
Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis.. 22 Suppl 2:B35-B39. 1999
Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes.. 22:191-197. 1999
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.. 22:233-240. 1999
Growth factors and the regulation of fetal growth.. 21 Suppl 2:B60-B69. 1998
Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. 19:1225-1228. 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.. 19:1225-1228. 1996
Feasibility and Acceptability of a Proposed Infant Feeding Intervention Trial for the Prevention of Type I Diabetes. 18:940-942. 1995
Cow's Milk Exposure and Type I Diabetes Mellitus: A critical overview of the clinical literature. 17:13-19. 1994
Emphysematous Pyelonephritis: Complicated Urinary Tract Infection in Diabetes. 12:229-232. 1989
Stress-Free Labor for the Diabetic Parturient. 9:555-556. 1986

Diabetes Care Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)